Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALIBU trial of ibrutinib + rituximab in untreated marginal zone lymphoma
2023-507886-25-00Phase 2Authorised
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and rituximab in marginal zone B-cell lymphoma (MZL), extranodal marginal zone B-cell lymphoma (EMZL), splenic marginal zone lymphoma (SMZL) and 1 more, sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Complete response rate at 12 months and Progression-free survival at 5 years. Planned start Sep 2019; status: authorised.
02
Drugs
ibrutinibrituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2023-507886-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507886-25-00.